AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2693180 — intervention group
Group type: COMPARATOR
Intervention: Lortat-Jacob procedure
Number of subjects: 52
Study 352468 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (150 mg daily)
Number of subjects: 32
Study 352468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31221205 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity counselling intervention
Number of subjects: 334
Study 31221205 — intervention group
Group type: COMPARATOR
Intervention: Placebo control condition (general instructions about health-enhancing physical activity)
Number of subjects: 334
Study 28870052 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS perioperative management
Number of subjects: 82
Study 28870052 — intervention group
Group type: COMPARATOR
Intervention: Traditional perioperative management (Control)
Number of subjects: 82
Study 26453638 — intervention group
Group type: EXPERIMENTAL
Intervention: Reusable Goldmann applanation prism
Number of subjects: 300
Study 26453638 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable Tonosafe prism
Number of subjects: 300
Study 26453638 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver variability across all observer groups
Number of subjects: 300
Study 23374268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralymphatic allergen-specific immunotherapy (ILIT) with 3 inguinal injections of ALK Alutard (1000 SQ-U birch pollen or grass pollen)
Number of subjects: 0
Study 23374268 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ALK diluent)
Number of subjects: 0
Study 24198648 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride topical gel (OTG)
Number of subjects: 727
Study 24198648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 727
Study 19815293 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin on alternate days
Number of subjects: 39876
Study 19815293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39876
Study 16904224 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 179
Study 16904224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligation
Number of subjects: 179
Study 14667511 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 0
Study 14667511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 0
Study 14667511 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 0
Study 11513383 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 6
Study 11513383 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 6
Study 9081358 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate 1.8 mg/kg
Number of subjects: 474
Study 9081358 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate 2.4 mg/kg
Number of subjects: 474
Study 9081358 — intervention group
Group type: COMPARATOR
Intervention: Granisetron 3 mg
Number of subjects: 474
Study 1862730 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 123
Study 1862730 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 123
Study 1862730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 6851036 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 2800
Study 6851036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2800
Study 29905976 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolapitant (IV) 18 mg
Number of subjects: 0
Study 29905976 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolapitant (IV) 36 mg
Number of subjects: 0
Study 29905976 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolapitant (IV) 54 mg
Number of subjects: 0
Study 29905976 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolapitant (IV)
Number of subjects: 0
Study 28382669 — intervention group
Group type: EXPERIMENTAL
Intervention: Peaceful Playgrounds™ (P2) intervention
Number of subjects: 4
Study 28382669 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 4
Study 25660991 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing DMARDs (arm 1)
Number of subjects: 101
Study 25660991 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering DMARDs by 50% (arm 2)
Number of subjects: 101
Study 25660991 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping DMARDs after 6 months tapering (arm 3)
Number of subjects: 101
Study 25660991 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all arms)
Number of subjects: 101
Study 24518124 — intervention group
Group type: EXPERIMENTAL
Intervention: Irsogladine (4 mg/day)
Number of subjects: 41
Study 24518124 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 41
Study 22018763 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosaccade task
Number of subjects: 11
Study 22018763 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisaccade task
Number of subjects: 11
Study 19571804 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) monotherapy
Number of subjects: 368
Study 19571804 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol monotherapy
Number of subjects: 368
Study 19571804 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ + atenolol combination therapy
Number of subjects: 368
Study 19571804 — intervention group
Group type: COMPARATOR
Intervention: Atenolol + HCTZ combination therapy
Number of subjects: 368
Study 19571804 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall BP control
Number of subjects: 368
Study 17882387 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiger tube (Cook)
Number of subjects: 28
Study 17882387 — intervention group
Group type: COMPARATOR
Intervention: Bengmark tube (Pfrimmer Nutricia)
Number of subjects: 28
Study 15167958 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 6367
Study 15167958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-smokers
Number of subjects: 6367
Study 15167958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmokers
Number of subjects: 6367
Study 12032419 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected intensity resistance exercise
Number of subjects: 19
Study 12032419 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed intensity resistance exercise (75% of 1RM)
Number of subjects: 19
Study 12032419 — intervention group
Group type: COMPARATOR
Intervention: Quiet rest control
Number of subjects: 19
Study 9617052 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol 1%
Number of subjects: 60
Study 9617052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanolamine oleate 5%
Number of subjects: 60
Study 9617052 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate
Number of subjects: 60
Study 7623725 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-radiotherapy chemotherapy (vincristine, procarbazine, methotrexate)
Number of subjects: 364
Study 7623725 — intervention group
Group type: COMPARATOR
Intervention: Reduced dose radiotherapy (25 Gy to the craniospinal axis)
Number of subjects: 364
Study 7623725 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy (35 Gy to the craniospinal axis)
Number of subjects: 364
Study 7623725 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-radiotherapy chemotherapy (vincristine and CCNU for high risk children)
Number of subjects: 364
Study 2259867 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin 11 mg/kg bw
Number of subjects: 29
Study 2259867 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin 15 mg/kg bw
Number of subjects: 29
Study 2259867 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin once daily dosing
Number of subjects: 29
Study 2259867 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin serum concentration monitoring
Number of subjects: 29
Study 7377745 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadiazine (SD) 500 mg twice daily
Number of subjects: 0
Study 7377745 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadiazine (SD) 250 mg twice daily
Number of subjects: 0
Study 7377745 — intervention group
Group type: COMPARATOR
Intervention: Sulfamethoxazole (SM) 1000 mg twice daily
Number of subjects: 0
Study 31991511 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron 50 mg
Number of subjects: 0
Study 31991511 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron 100 mg
Number of subjects: 0
Study 31991511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31991511 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron 50 mg and 100 mg
Number of subjects: 0
Study 30132051 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing (RP)
Number of subjects: 49
Study 30132051 — intervention group
Group type: COMPARATOR
Intervention: No patellar resurfacing (non-RP)
Number of subjects: 49
Study 27641003 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone 8.3 mg kg‐1
Number of subjects: 18
Study 27641003 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone 16.7 mg kg‐1
Number of subjects: 18
Study 27641003 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone 33.3 mg kg‐1
Number of subjects: 18
Study 25982057 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused Attention Meditation (FAM)
Number of subjects: 0
Study 25982057 — intervention group
Group type: COMPARATOR
Intervention: Open Monitoring Meditation (OMM)
Number of subjects: 0
Study 24083367 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based Bayesian algorithm
Number of subjects: 65
Study 24083367 — intervention group
Group type: COMPARATOR
Intervention: Manual nurse decision process
Number of subjects: 65
Study 21244439 — intervention group
Group type: EXPERIMENTAL
Intervention: Kudzu extract (total isoflavone dose of 750 mg/d)
Number of subjects: 12
Study 21244439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19961042 — intervention group
Group type: EXPERIMENTAL
Intervention: eperisone 300 mg/day
Number of subjects: 18
Study 19961042 — intervention group
Group type: COMPARATOR
Intervention: eperisone 150 mg/day
Number of subjects: 18
Study 19961042 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 18190257 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) twice-daily therapy
Number of subjects: 228
Study 18190257 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) once-daily therapy
Number of subjects: 228
Study 15045702 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic lipase deficiency patients
Number of subjects: 8
Study 11254910 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg twice daily
Number of subjects: 48
Study 11254910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 9462248 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS (whole blood)
Number of subjects: 48
Study 8187257 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% oxygen during TIVAK
Number of subjects: 140
Study 8187257 — intervention group
Group type: COMPARATOR
Intervention: Room air during TIVAK
Number of subjects: 140
Study 3122575 — intervention group
Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotropin (150 U administered hourly)
Number of subjects: 10
Study 3122575 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone (75 ng/kg administered hourly)
Number of subjects: 10
Study 30618880 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual support group
Number of subjects: 201
Study 30618880 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-education group
Number of subjects: 201
Study 30618880 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 201
Study 27046320 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (12-week open-label phase followed by a 40-week randomized, placebo-controlled phase)
Number of subjects: 65
Study 27046320 — intervention group
Group type: COMPARATOR
Intervention: Placebo (40-week randomized, placebo-controlled phase)
Number of subjects: 65
Study 25761501 — intervention group
Group type: EXPERIMENTAL
Intervention: Before treatment for intestinal parasites
Number of subjects: 21
Study 25761501 — intervention group
Group type: EXPERIMENTAL
Intervention: After successful antiparasitic treatment
Number of subjects: 21
Study 23050945 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine (Artrox®) 625 mg twice daily
Number of subjects: 34
Study 23050945 — intervention group
Group type: COMPARATOR
Intervention: Control (Vitamineral® multivitamin tablet)
Number of subjects: 34
Study 23050945 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin group
Number of subjects: 34
Study 20649492 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory electrical stimulation (ES)
Number of subjects: 6
Study 20649492 — intervention group
Group type: COMPARATOR
Intervention: Control sham intervention
Number of subjects: 6
Study 17979080 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic physical exercises over a 12-week programme
Number of subjects: 28
Study 17979080 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 28
Study 15908764 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole 10 mg once daily
Number of subjects: 84
Study 15908764 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 300 mg once daily
Number of subjects: 84
Study 12479049 — intervention group
Group type: EXPERIMENTAL
Intervention: External RF hyperthermia (ERFH) combined with alpha 1-adrenergic receptor blocker Terazosin for 12 weeks
Number of subjects: 136
Study 12479049 — intervention group
Group type: COMPARATOR
Intervention: External RF hyperthermia (ERFH)
Number of subjects: 136
Study 9656040 — intervention group
Group type: EXPERIMENTAL
Intervention: Instillation of 5‐mL bolus of normal saline before suctioning
Number of subjects: 29
Study 9656040 — intervention group
Group type: COMPARATOR
Intervention: No instillation of normal saline before suctioning (Control)
Number of subjects: 29
Study 9656040 — intervention group
Group type: EXPERIMENTAL
Intervention: Instillation of normal saline before suctioning
Number of subjects: 29
Study 8134215 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Home Care (PHC)
Number of subjects: 219
Study 8134215 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 219
Study 2777428 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-filled capsules (20 mg)
Number of subjects: 10
Study 2777428 — intervention group
Group type: COMPARATOR
Intervention: Slow-release tablets (20 mg)
Number of subjects: 10
Study 1120220 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 tablets
Number of subjects: 0
Study 1120220 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 0
Study 31345559 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol + dexmedetomidine 0.4 μg/kg
Number of subjects: 120
Study 31345559 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol + ketamine 0.4 mg/kg
Number of subjects: 120
Study 31345559 — intervention group
Group type: COMPARATOR
Intervention: propofol + saline (control group)
Number of subjects: 120
Study 30517575 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes compression (G30)
Number of subjects: 303
Study 30517575 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 minutes compression (G60)
Number of subjects: 303
Study 25941053 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (mobile-team outreach)
Number of subjects: 0
Study 25941053 — intervention group
Group type: COMPARATOR
Intervention: Control (not exposed to the intervention)
Number of subjects: 0
Study 25941053 — intervention group
Group type: EXPERIMENTAL
Intervention: Brothel-based female sex workers
Number of subjects: 0
Study 24142540 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 50
Study 24142540 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 50
Study 22913464 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot trial involving qualitative interviews with service providers and participants (children and parents)
Number of subjects: 21
Study 22913464 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with four dentists and 17 dental team members
Number of subjects: 21
Study 22913464 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face interviews with four parents and children, and five telephone interviews with parents
Number of subjects: 21
Study 21039673 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride
Number of subjects: 1455
Study 17657860 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal protection device (PercuSurge GuardWire; GW)
Number of subjects: 112
Study 17657860 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GW protection)
Number of subjects: 112
Study 16277179 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence cystoscopy
Number of subjects: 109
Study 16277179 — intervention group
Group type: COMPARATOR
Intervention: Standard white light endoscopy
Number of subjects: 109
Study 12411094 — intervention group
Group type: EXPERIMENTAL
Intervention: Video viewing plus education with talk
Number of subjects: 648
Study 12411094 — intervention group
Group type: EXPERIMENTAL
Intervention: Video viewing
Number of subjects: 648
Study 12411094 — intervention group
Group type: COMPARATOR
Intervention: Control group (A)
Number of subjects: 648
Study 9707653 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 micrograms of intradermal (ID) capsaicin (CAP) to the volar forearm with skin temperature fixed at 36 degrees C (36 ID)
Number of subjects: 12
Study 9707653 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 micrograms ID CAP with varying skin temperature (VT ID)
Number of subjects: 12
Study 9707653 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microliters of 1% CAP patch placed on the skin at 36 degrees C (Topical)
Number of subjects: 12
Study 9707653 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms ID CAP in the volar forearm or foot dorsum
Number of subjects: 12
Study 7851554 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 40
Study 7851554 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ultrasound
Number of subjects: 40
Study 7851554 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of laparoscopy and laparoscopic ultrasound
Number of subjects: 40
Study 2693432 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course tobramycin and cefoperazone (discontinued at day four)
Number of subjects: 195
Study 2693432 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin plus cefoperazone (continued for up to 26 days)
Number of subjects: 195
Study 2693432 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin plus mezlocillin (continued for up to 26 days)
Number of subjects: 195
Study 2693432 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course tobramycin therapy
Number of subjects: 195
Study 2693432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone (after day four)
Number of subjects: 195
Study 2693432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone (not associated with vitamin K)
Number of subjects: 195
Study 2693432 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocytopenia recovery
Number of subjects: 195
Study 2693432 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial episodes of fever related to documented infections
Number of subjects: 195
Study 2693432 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteraemia, pneumonia or Gram-positive aerobic or Pseudomonas aeruginosa infections
Number of subjects: 195
Study 352710 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide lactam, methyloxazepam and oxazepam
Number of subjects: 40
Study 352710 — intervention group
Group type: EXPERIMENTAL
Intervention: N-desmethyl-diazepam
Number of subjects: 40
Study 352710 — intervention group
Group type: COMPARATOR
Intervention: Alcohol
Number of subjects: 40
Study 31848765 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered mindfulness training (MT)
Number of subjects: 42
Study 31848765 — intervention group
Group type: COMPARATOR
Intervention: Health coaching (HC)
Number of subjects: 42
Study 31848765 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MT and HC
Number of subjects: 42
Study 30600526 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal sufentanil (0.4 μg/kg)
Number of subjects: 144
Study 30600526 — intervention group
Group type: COMPARATOR
Intervention: IV-only multimodal analgesics (control group)
Number of subjects: 144
Study 27930926 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone with prolonged exposure (PE)
Number of subjects: 165
Study 27930926 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone without prolonged exposure (PE)
Number of subjects: 165
Study 27930926 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with prolonged exposure (PE)
Number of subjects: 165
Study 27930926 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo without prolonged exposure (PE)
Number of subjects: 165
Study 27930926 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling (BRENDA) alone
Number of subjects: 165
Study 25383689 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Kindness Curriculum (KC)
Number of subjects: 68
Study 25383689 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 23163747 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominance strategy
Number of subjects: 0
Study 23163747 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestige strategy
Number of subjects: 0
Study 21319897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) intervention, 8-week group during pregnancy and 3 individual booster sessions postpartum
Number of subjects: 217
Study 21319897 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 217
Study 21319897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) intervention
Number of subjects: 217